Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial.

ABSTRACT:

Objective

To determine whether increasing the dose of ulipristal acetate (UPA)-containing emergency contraception (EC) improves pharmacodynamic outcomes in individuals with obesity.

Study design

We enrolled healthy, regularly-cycling, confirmed ovulatory, reproductive-age individuals with body mass index (BMI) >30 kg/m² and weight >80 kg in a randomised crossover study. We monitored participants with transvaginal ultrasound and blood sampling for progesterone, luteinising hormone (LH), and estradiol every other day until a dominant follicle measuring >15 mm was visualised. At that point, participants received either oral UPA EC 30 mg or 60 mg and returned for daily monitoring up to 7 days. After a no treatment washout cycle, participants returned for a second moni

SUBMITTER: Edelman A 

PROVIDER: S-EPMC11703681 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature